ABSTRACT
The efficacy of mesotherapy in the treatment of female pattern hair loss (FPHL) has not yet been evaluated. Aim of the study was to compare the initial efficacy and safety of mesotherapy containing nutritional supplements to topical minoxidil 5% solution in FPHL. 30 patients with FPHL were randomly classified into two equal groups: Group A applied minoxidil 5% lotion twice daily; Group B was injected with mesotherapy once weekly. For both groups ultrasound biomicroscopy (UBM) was performed before and at the end of the 12th week of treatment. After treatment, no significant difference was found between both groups with regard to either improvement of hair density and hair loss (P=0.27 and 0.056, respectively), nor the degree of improvement of Ludwig's classification as assessed by the investigator (P=0.210). A significant difference was observed between both groups (P=0.001) with the highest degree of satisfaction in the mesotherapy group. In group A, no significant difference was found in the number of hair follicles or the diameter of the largest hair follicle (P=0.244 and 0.925, respectively). In group B, a significant difference was found in the number of hair follicles (P=0.001), with no significant difference in the diameter of the largest hair follicle (P=0.105). The mesotherapy group showed more improvement with regard to the increase in the number of the hair follicles after treatment (P=0.007). Limitation of the study is small sample size, and relatively short duration of treatment. Mesotherapy, containing nutritional supplements only, is an effective, more acceptable to patients, and more tolerable modality compared with topical minoxidil in the treatment of FPHL.
Subject(s)
Alopecia/therapy , Mesotherapy , Minoxidil/administration & dosage , Vasodilator Agents/administration & dosage , Administration, Topical , Adult , Female , Humans , Microscopy, Acoustic , Middle Aged , Patient Satisfaction , Treatment OutcomeABSTRACT
New treatment modalities for vitiligo acting by changing certain cytokines and metalloproteinases are newly emerging. The aim of this work is to To assess the efficacy of trichloroacetic acid (TCA) chemical peel, dermapen, and fractional CO2 laser in treatment of stable non-segmental vitiligo and to detect their effects on IL-17 and MMP-9 levels. Thirty patients with stable vitiligo were recruited in a randomized controlled study. They were randomly categorized into three equal groups. Group 1: TCA peel, Group 2: dermapen machine, and Group 3: Fractional CO2 laser. Skin biopsies were taken from treated areas and from control areas for which MMP-9 and IL-17 tissue levels were measured using ELISA. The 30 vitiligo patients had low basal tissue MMP-9 levels and high baseline IL-17 tissue levels. As regards the three different used modalities, all of them caused rise in MMP-9 as well as IL-17 levels and almost their levels were much more elevated with repetition of the previously mentioned traumatic procedures. TCA 25% peel proved to be the most effective modality both clinically and laboratory and it can be used prior or with other conventional therapies in the treatment of vitiligo.
Subject(s)
Caustics/administration & dosage , Chemexfoliation , Cosmetic Techniques , Lasers, Gas/therapeutic use , Low-Level Light Therapy/instrumentation , Skin Pigmentation , Skin , Trichloroacetic Acid/administration & dosage , Vitiligo/therapy , Administration, Cutaneous , Adolescent , Adult , Biopsy , Caustics/adverse effects , Chemexfoliation/adverse effects , Cosmetic Techniques/adverse effects , Cosmetic Techniques/instrumentation , Egypt , Female , Humans , Interleukin-17/metabolism , Lasers, Gas/adverse effects , Low-Level Light Therapy/adverse effects , Male , Matrix Metalloproteinase 9/metabolism , Middle Aged , Miniaturization , Needles , Skin/drug effects , Skin/enzymology , Skin/immunology , Skin/radiation effects , Skin Pigmentation/drug effects , Skin Pigmentation/radiation effects , Time Factors , Treatment Outcome , Trichloroacetic Acid/adverse effects , Vitiligo/diagnosis , Vitiligo/enzymology , Vitiligo/immunology , Young AdultABSTRACT
To study protection of melanocytes from stress-induced cell death by heme oxygenases during depigmentation and repigmentation in vitiligo, expression of isoforms 1 and 2 was studied in cultured control and patient melanocytes and normal skin explants exposed to UV or bleaching agent 4-TBP. Similarly, expression of heme oxygenases was followed in skin from vitiligo patients before and after PUVA treatment. Single and double immunostainings were used in combination with light and confocal microscopic analysis and Western blotting. Melanocyte expression of heme oxygenase 1 is upregulated, whereas heme oxygenase 2 is reduced in response to UV and 4-TBP. Upregulation of inducible heme oxygenase 1 was also observed in UV-treated explant cultures, in skin of successfully PUVA-treated patients and in melanocytes cultured from vitiligo non-lesional skin. Heme oxygenase encoding genes were subsequently cloned to study consequences of either gene product on cell viability, demonstrating that HO-1 but not HO-2 overexpression offers protection from stress-induced cell death in MTT assays. HO-1 expression by melanocytes may contribute to beneficial effects of UV treatment for vitiligo patients.
Subject(s)
Heme Oxygenase-1/metabolism , Melanocytes/enzymology , Melanocytes/pathology , Vitiligo/enzymology , Vitiligo/pathology , Antioxidants/metabolism , Base Sequence , Cell Death/drug effects , Cell Death/physiology , Cell Death/radiation effects , Cells, Cultured , Endoplasmic Reticulum/enzymology , Heme Oxygenase (Decyclizing)/genetics , Heme Oxygenase (Decyclizing)/metabolism , Heme Oxygenase-1/genetics , Humans , Melanocytes/radiation effects , Oxidative Stress , PUVA Therapy , RNA/genetics , RNA/metabolism , Ultraviolet Rays , Up-Regulation/radiation effects , Vitiligo/drug therapyABSTRACT
PUVA is the first therapeutic choice in early stages of mycosis fungoides (MF). In this study the effect of PUVA on bcl-2 expression in MF was assessed in 15 patients (three stage Ia and 12 stage Ib) and 10 controls. Two biopsies were taken from each patient before and after 24 sessions of PUVA therapy. Histopathological assessment and immunohistochemical staining for bcl-2 was performed and showed positive bcl-2 staining of lymphocytes in 53% of MF cases (8/15) before PUVA, with no statistically significant difference in the bcl-2 level before and after PUVA therapy (P value 0.3). A statistically significant difference was found in the bcl-2 level between control samples and MF patients' biopsies before (P value 0.02) and after PUVA therapy (P value 0.011). In conclusion, a lack of decline in the bcl-2 level and the absence of clinical or histopathological correlation with the bcl-2 level before and after PUVA therapy in MF patients suggest that PUVA-induced apoptosis in MF cases may occur through pathways other than bcl-2 inhibition.